<abstract xml:lang="en" xmlns="http://www.w3.org/1999/xhtml"><bold>Introduction.</bold> Meningiomas are intracranial brain tumours that frequently recur. Recurrence rates up to 20% in 20 years for benign meningiomas, up to 80% for atypical meningiomas and up to 100% for malignant meningiomas, have been reported. The most important prognostic factors for meningioma recurrence are meningioma grade, meningioma invasiveness and radicality of neurosurgical resection. The aim of our study was to evaluate the differences in antigenic expression on the surface of meningioma cells between recurrent and non-recurrent meningiomas.<bold>Methods.</bold> 19 recurrent meningiomas and 35 non-recurrent meningiomas were compared regarding the expression of MIB-1 antigen, progesterone receptors, cathepsin B and cathepsin L, using immunohistochemistry.<bold>Results.</bold> MIB-1 antigen expression was higher in the recurrent meningioma group (p=0.001). No difference in progesterone receptor status between recurrent and non-recurrent meningiomas was confirmed. Immunohistochemical intensity scores for cathepsin B (p= 0.007) and cathepsin L (p&lt;0.001) were both higher in the recurrent than in the non-recurrent meningioma group.<bold>Conslusions.</bold> MIB-1 antigen expression is higher in recurrent compared to non-recurrent meningiomas. There is no difference in expression of progesterone receptors between recurrent and non-recurrent meningiomas. Cathepsins B and L are expressed more in recurrent meningiomas.</abstract>

Introduction. Meningiomas are intracranial brain tumours that frequently recur. Recurrence rates up to 20% in 20 years for benign meningiomas, up to 80% for atypical meningiomas and up to 100% for malignant meningiomas, have been reported. The most important prognostic factors for meningioma recurrence are meningioma grade, meningioma invasiveness and radicality of neurosurgical resection. The aim of our study was to evaluate the differences in antigenic expression on the surface of meningioma cells between recurrent and non-recurrent meningiomas.Methods. 19 recurrent meningiomas and 35 non-recurrent meningiomas were compared regarding the expression of MIB-1 antigen, progesterone receptors, cathepsin B and cathepsin L, using immunohistochemistry.Results. MIB-1 antigen expression was higher in the recurrent meningioma group (p=0.001). No difference in progesterone receptor status between recurrent and non-recurrent meningiomas was confirmed. Immunohistochemical intensity scores for cathepsin B (p= 0.007) and cathepsin L (p<0.001) were both higher in the recurrent than in the non-recurrent meningioma group.Conslusions. MIB-1 antigen expression is higher in recurrent compared to non-recurrent meningiomas. There is no difference in expression of progesterone receptors between recurrent and non-recurrent meningiomas. Cathepsins B and L are expressed more in recurrent meningiomas.

Antigen expression on recurrent meningioma cells

Department of Neurosurgery, University Medical Centre Ljubljana, Ljubljana, Slovenia

Radiology and Oncology

{"article-title":"Antigen expression on recurrent meningioma cells"}

Introduction. Meningiomas are intracranial brain tumours that frequently recur. Recurrence rates up to 20% in 20 years for benign meningiomas, up to 80% for...

Antigen expression on recurrent meningioma cells

Data publikacji: 24 maj 2010

Zakres stron: 107 - 112

DOI: https://doi.org/10.2478/v10019-010-0028-6

Słowa kluczowe
meningioma, recurrence, tumour markers, proliferation index, MIB-1 antigen, cathepsin B, cathepsin L

This content is open access.

Antigen expression on recurrent meningioma cells

Data publikacji: 24 maj 2010

Zakres stron: 107 - 112

DOI: https://doi.org/10.2478/v10019-010-0028-6

Słowa kluczowemeningioma, recurrence, tumour markers, proliferation index, MIB-1 antigen, cathepsin B, cathepsin L

This content is open access.

Słowa kluczowe
meningioma, recurrence, tumour markers, proliferation index, MIB-1 antigen, cathepsin B, cathepsin L